Example Medications Appropriate for Administration by Pharmacists

Total Page：16

File Type：pdf, Size：1020Kb

Example Medications Appropriate for Administration by Pharmacists Generic Name Representative Brand Name Medication Class Abatacept Orencia Immunosuppressant Adalimumab Humira Antirheumatic; monoclonal antibody; tumor necrosis factor inhibitor Aripiprazole Abilify Maintena Antipsychotic Aripiprazole lauroxil Aristada Antipsychotic Certolizumab pegol Cimzia Immune suppressant; monoclonal antibody fragment; tumor necrosis factor inhibitor Coagulation factor IX AlphaNine SD; Mononine Antihemophilic agent Cyanocobalamin Vitamin B1 Vitamin B12 Dalteparin sodium Fragmin Anticoagulant; low-molecular-weight heparin Darbepoetin alfa Aranesp Erythropoietic; hematopoietic Denosumab Prolia Immunological agent; monoclonal antibody Enoxaparin sodium Lovenox Anticoagulant; low-molecular-weight heparin Epoetin alfa Epogen; Procrit Erythropoietic; hematopoietic Etanercept Enbrel Immune suppressant; tumor necrosis factor inhibitor Filgrastim Neupogen Colony-stimulating factor; hematopoietic Fluphenazine deconate Prolixin Antipsychotic; phenothiazine; piperazine Glatiramer acetate Copaxone; Glatopa Central nervous system agent; immune suppressant Golimumab Simponi Immune modulator; monoclonal antibody; tumor necrosis factor inhibitor Haloperidol decanoate Haldol Antipsychotic; butyrophenone; dopamine antagonist APhA Implementation Toolkit for Pharmacy-based Medication Administration Services Generic Name Representative Brand Name Medication Class Interferon beta-1a Avonex; Rebif Immunological agent; beta interferon Interferon beta-1b Betaseron; Extavia Immunological agent; beta interferon Leuprolide acetate Eligard; Lupron; Viadur Antineoplastic agent; endocrine- metabolic agent; endometrial hyperplasia agent; luteinizing hormone–releasing hormone agonist Medroxyprogesterone Depo-Provera Antineoplastic agent; progestin acetate contraceptive; endocrine-metabolic agent; progestin Methotrexate Otrexup; Rasuvo; Antimetabolite; antineoplastic agent Rheumatrex; Trexall Naltrexone Vivitrol Ethanol dependency; opioid antagonist Octreotide acetate Sandostatin Endocrine-metabolic agent; somatostatin Olanzapine Zyprexa Antipsychotic; thienobenzodiazepine Omalizumab Xolair Antiasthma; monoclonal antibody Paliperidone palmitate Invega Sustenna; Invega Antipsychotic; benzisoxazole Trinza Pegfilgrastim Neulasta Colony-stimulating factor; hematopoietic Risperidone Risperdal Consta Antipsychotic; benzisoxazole Secukinumab Cosentyx Antipsoriatic; monoclonal antibody Teriparatide Forteo Calcium regulator; parathyroid hormone analog Testosterone cypionate Depo-Testosterone Androgen; endocrine-metabolic agent Tocilizumab Actemra Immunological agent; monoclonal antibody Ustekinumab Stelara Immunological agent; monoclonal antibody Ziprasidone mesylate Geodon Atypical antipsychotic This list provides examples of medications appropriate for administration by pharmacists. It should not be considered an all-inclusive list. APhA Implementation Toolkit for Pharmacy-based Medication Administration Services.

Copy Link

Recommended publications

NIH Public Access Author Manuscript Bioorg Med Chem
NIH Public Access Author Manuscript Bioorg Med Chem. Author manuscript; available in PMC 2013 February 01. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Bioorg Med Chem. 2012 February 1; 20(3): 1291–1297. doi:10.1016/j.bmc.2011.12.019. Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents Kwakye Pepraha, Xue Y. Zhua, Suresh V. K. Eyunnia, Vincent Setolab, Bryan L. Rothb, and Seth Y. Ablordeppey*,a aDivision of Basic Pharmaceutical Sciences, Florida A&M University, College of Pharmacy and Pharmaceutical Sciences, Tallahassee, FL 32307, USA bDepartment of Pharmacology, Medicinal Chemistry and Psychiatry, University of North Carolina at Chapel Hill, School of Medicine, NC 27599, USA Abstract Using haloperidol as a scaffold, new agents were designed to investigate the structural contributions of various groups to binding at CNS receptors associated with atypical antipsychotic pharmacology. It is clear that each pharmacophoric group, the butyrophenone, the piperidine and the 4-chlorophenyl moieties contributes to changes in binding to the receptors of interest. This strategy has resulted in the identification of several new agents, compounds 16, 18, 19, 23, 24 and 25, with binding profiles which satisfy our stated criteria for agents to act as potential atypical antipsychotics. This research demonstrates that haloperidol can serve as a useful lead in the identification and design of new agents that target multiple receptors
[Show full text]
Adverse Reactions to Hallucinogenic Drugs. 1Rnstttutton National Test
DOCUMENT RESUME ED 034 696 SE 007 743 AUTROP Meyer, Roger E. , Fd. TITLE Adverse Reactions to Hallucinogenic Drugs. 1rNSTTTUTTON National Test. of Mental Health (DHEW), Bethesda, Md. PUB DATP Sep 67 NOTE 118p.; Conference held at the National Institute of Mental Health, Chevy Chase, Maryland, September 29, 1967 AVATLABLE FROM Superintendent of Documents, Government Printing Office, Washington, D. C. 20402 ($1.25). FDPS PRICE FDPS Price MFc0.50 HC Not Available from EDRS. DESCPTPTOPS Conference Reports, *Drug Abuse, Health Education, *Lysergic Acid Diethylamide, *Medical Research, *Mental Health IDENTIFIEPS Hallucinogenic Drugs ABSTPACT This reports a conference of psychologists, psychiatrists, geneticists and others concerned with the biological and psychological effects of lysergic acid diethylamide and other hallucinogenic drugs. Clinical data are presented on adverse drug reactions. The difficulty of determining the causes of adverse reactions is discussed, as are different methods of therapy. Data are also presented on the psychological and physiolcgical effects of L.S.D. given as a treatment under controlled medical conditions. Possible genetic effects of L.S.D. and other drugs are discussed on the basis of data from laboratory animals and humans. Also discussed are needs for futher research. The necessity to aviod scare techniques in disseminating information about drugs is emphasized. An aprentlix includes seven background papers reprinted from professional journals, and a bibliography of current articles on the possible genetic effects of drugs. (EB) National Clearinghouse for Mental Health Information VA-w. Alb alb !bAm I.S. MOMS Of NAM MON tMAN IONE Of NMI 105 NUNN NU IN WINES UAWAS RCM NIN 01 NUN N ONMININI 01011110 0.
[Show full text]
Appendix 13C: Clinical Evidence Study Characteristics Tables
APPENDIX 13C: CLINICAL EVIDENCE STUDY CHARACTERISTICS TABLES: PHARMACOLOGICAL INTERVENTIONS Abbreviations ............................................................................................................ 3 APPENDIX 13C (I): INCLUDED STUDIES FOR INITIAL TREATMENT WITH ANTIPSYCHOTIC MEDICATION .................................. 4 ARANGO2009 .................................................................................................................................. 4 BERGER2008 .................................................................................................................................... 6 LIEBERMAN2003 ............................................................................................................................ 8 MCEVOY2007 ................................................................................................................................ 10 ROBINSON2006 ............................................................................................................................. 12 SCHOOLER2005 ............................................................................................................................ 14 SIKICH2008 .................................................................................................................................... 16 SWADI2010..................................................................................................................................... 19 VANBRUGGEN2003 ....................................................................................................................
[Show full text]
Aromaticity of Anthranil and Its Isomers, 1,2-Benzisoxazole and Benzoxazole Carmen Domene,A Leonardus W
Tetrahedron Letters Tetrahedron Letters 46 (2005) 4077–4080 Aromaticity of anthranil and its isomers, 1,2-benzisoxazole and benzoxazole Carmen Domene,a Leonardus W. Jenneskensb,* and Patrick W. Fowlerc aPhysical and Theoretical Chemistry Laboratory, Oxford University, South Parks Road, Oxford OX1 3QZ, UK bDebye Institute, Organic Chemistry and Catalysis, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands cDepartment of Chemistry, University of Exeter, Stocker Road, Exeter EX4 4QD, UK Received 14 February 2005; revised 28 March 2005; accepted 5 April 2005 Available online 19 April 2005 Abstract—Direct computation of the p-current density, that is, the Ôring currentÕ, of anthranil (1) and its isomers 1,2-benzisoxazole (2) and benzoxazole (3) reveals different patterns of current flow: isomers 2 and 3 sustain strong benzene-like currents in the six- membered and bifurcated flow in the five-membered ring, whereas, in keeping with its lower thermodynamic stability, 1 has only a perimeter circulation without separate monocycle currents. Although the ring current criterion does not offer a sharp distinction between 2 and 3, their difference in thermodynamic stability is identical to that between isoxazole (4) and oxazole (5) suggesting an aromaticity order 1 < 2 3. Ó 2005 Elsevier Ltd. All rights reserved. The extent to which energetic, reactivity and magnetic property underlying NICS: the current density induced criteria of aromaticity are descriptions of a single, unify- by a perpendicular magnetic field, that is, the Ôring ing property of molecules remains a matter of debate.1 currentÕ, which gives an insight into the essential differ- Anthranil (1) and its isomers 1,2-benzisoxazole (2) and ence between anthranil (1) on the one hand and its benzoxazole (3) offer a series of bicyclic molecules with two isomers 2 and 3 on the other.
[Show full text]
Pharmaceutical Appendix to the Tariff Schedule 2
Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
[Show full text]
Studies with Lysergic Acid Diethylamide in Regressed Schizophrenics
CHAPTER 15 _ Studies with Lysergic Acid Diethylamide in Regressed Schizophrenics By FREDERICK B. CHARAT AN, M.D. OF THE MANY studies carried out with lysergic acid diethylamide in the last 15 years, relatively few have dealt with regressed schizophrenics. Most workers have used comparatively small doses of LSD. Some gave up to 600 gamma orally. Others reported the effects of up to 500 gamma intra- muscularly, 180 gamma intravenously and 60 gamma intrathecally in small series of cases. Several investigators agreed that in chronic schizophrenics higher doses of LSD than those administered to undeteriorated schizo- phrenics and nonpsychotics have been required to produce psychic effects. Apart from the slight response of chronic schizophrenics to doses of LSD which lead to marked and characteristic effects in other subjects, tolerance to the drug seems to develop in as brief a period as three days. These differences in response to LSD pose some interesting problems. Is the lack of response in chronic schizophrenics merely an apparent one caused by their inability to communicate their inner experiences? Is it due to the development of some immune state connected with biochemical alter- ations produced during the psychosis? Is it the reflection of a metabolic difference between schizophrenics and non-schizophrenics? May it be a general manifestation of schizophrenic underresponsiveness to virtually any stress, once the chronic stagnant phase of the psychosis has been reached? Clear answers to all these questions cannot yet be given. The present investi- gation was undertaken to examine further the responses of chronic schizo- phrenics to large doses of LSD and also to observe the effect of other drugs upon this response.
[Show full text]
Perphenazine-151548-PI.Pdf
PRESCRIBING INFORMATION PERPHENAZINE Perphenazine Tablets USP 2 mg , 4 mg, 8mg, and 16 mg Antipsychotic/Antiemetic AA Pharma Inc. DATE OF REVISION: April 12, 2012 1165 Creditsone Road, Unit #1 Vaughan, Ontario L4K 4N7 Control Number: 151548 PRESCRIBING INFORMATION PERPHENAZINE Perphenazine Tablets USP 2 mg, 4 mg, 8 mg and 16 mg THERAPEUTIC CLASSIFICATION Antipsychotic/Antiemetic ACTIONS AND CLINICAL PHARMACOLOGY Perphenazine is a piperazine phenothiazine derivative with antipsychotic, antiemetic and weak sedative activity. Perphenazine has actions similar to those of other phenothiazine derivatives but appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depressants and anesthetics. However, it produces a high incidence of extrapyramidal reactions. Perphenazine is well absorbed from the gastrointestinal tract. Onset of action following oral administration is 30 to 40 minutes. Duration of action is 3 to 4 hours. Perphenazine distributes to most body tissues with high concentrations being distributed into liver and spleen. Perphenazine enters the enterohepatic circulation and is excreted chiefly in the feces. INDICATIONS AND CLINICAL USE Perphenazine is indicated in the management of manifestations of psychotic disorders. It is also effective in controlling nausea and vomiting due to stimulation of the chemoreceptor trigger zone. 1 Perphenazine has not been shown effective for the management of behavioral complications in patients with mental retardation. CONTRAINDICATIONS Should not be administered in the presence of circulatory collapse, altered states of consciousness or comatose states, particularly when these are due to intoxication with central depressant drugs (alcohol, hypnotics, narcotics). It is contraindicated in severely depressed patients, in the presence of blood dyscrasias, liver disease, renal insufficiency, pheochromocytoma, or in patients with severe cardiovascular disorders or a history of hypersensitivity to phenothiazine derivatives.
[Show full text]
Preparation of Metabolites by Chemical Reaction: Conversion of Antipsychotic Phenothiazines to Their Sulfoxides and Tertiary
396 Journal of Health Science, 50(4) 396–406 (2004) Preparation of Metabolites N-oxides from parent drug could be confirmed when the collisional energy was decreased to 10 eV. 1H- and by Chemical Reaction: 13C-NMR spectral data confirmed the structure of the Conversion of Antipsychotic prepared mianserin N-oxide to be 2-oxide. In conclu- sion, a simple and rapid preparation method for oxide Phenothiazines to their metabolites of phenothiazines and tertiary amino cy- Sulfoxides and Tertiary clic antidepressants available as analytical standards was established. Amino Cyclic Key words —–— metabolite, chemical preparation, ox- Antidepressants ide, phenothiazine, cyclic antidepressants, mass spectros- to their N-Oxide with copy Hydrogen Peroxide Using Titanosilicate INTRODUCTION Catalyst The identification and quantification of drugs Akira Ogamo* and Mariko Fukumoto ingested into human bodies require comprehensive information covering the target drugs themselves and School of Pharmaceutical Sciences, Kitasato University, their metabolites. To carry out a quantitative analy- Shirokane 5–9–1, Minato-ku, Tokyo 108–8641, Japan sis, the standard substances of metabolites are es- (Received March 5, 2004; Accepted April 11, 2004) sential. Some important metabolites can be obtained as commercial products, but many metabolites, es- The aim of this study was to establish a prepara- pecially those of new drugs, are difficult to obtain tion method needed to analyze the metabolites of an as standard samples. These problems have been analytical procedure for antipsychotic phenothiazines solved by using experimental animals or isolated and tertiary amino cyclic antidepressants by chemical enzyme systems originating from biological mate- reaction. These drugs were oxidized to their sulfoxide rials.
[Show full text]
Phenothiazine Poisoning a Review of 48 Cases
Refer to: Barry D, Meyskens FL Jr, Becker CE: Phenothiazine poison- ing-A review of 48 cases. Calif Med 118:1-5, Jan 1973 California Medicine THE WESTERN JOURNAL OF MEDICINE Phenothiazine Poisoning A Review of 48 Cases DANIEL BARRY, B.A., FRANK L. MEYSKENS, JR., M.D., AND CHARLES E. BECKER, M.D., San Francisco * Of 48 cases of phenothiazine poisoning that were analyzed, 34 were attributed to stuicide attempts, nine to accidental ingestion, and five to drug reactions. As outpatient treatment of schizophrenia increases, cases of over- dose with phenothiazine drugs may be expected to increase also. The prescribing of multiple phenothiazines and antidepressants is probably contributory to the occurrence of mixed drug ingestions. The symptoms and signs of phenothiazine poisoning are largely predictable if the atropine-like, alpha-blocking, quinidine-like, and extrapyramidal actions of phenothiazines are appreciated, Unexplain- able tachypnea and paradoxical miosis were noted in severe cases. In one case in the study phenothiazine intoxication was present in the newborn infant of a schizophrenic mother. PHENOTHIAZINES ARE BECOMING household drugs tionable advertising campaigns advocating phe- in Califomnia. The closing of state hospitals with nothiazines for the treatment of a wide variety the concomitant institution of mass outpatient of ailments have made these drugs generally treatment of chronic schizophrenics through com- available. The high incidence of schizophrenia munity mental health centers, and recent quesv in young adulthood and the increasing suicide From the Detoxification Unit, San Francisco General Hospital, and rate in this age group" suggest that phenothia- the Department of Clinical Pharmacology, University of California, San Francisco.
[Show full text]
Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics
pharmaceutics Review Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics Francisco José Toja-Camba 1,2,† , Nerea Gesto-Antelo 3,†, Olalla Maroñas 3,†, Eduardo Echarri Arrieta 4, Irene Zarra-Ferro 2,4, Miguel González-Barcia 2,4 , Enrique Bandín-Vilar 2,4 , Victor Mangas Sanjuan 2,5,6 , Fernando Facal 7,8 , Manuel Arrojo Romero 7, Angel Carracedo 3,9,10,* , Cristina Mondelo-García 2,4,* and Anxo Fernández-Ferreiro 2,4,* 1 Pharmacy Department, University Clinical Hospital of Ourense (SERGAS), Ramón Puga 52, 32005 Ourense, Spain; [email protected] 2 Clinical Pharmacology Group, Institute of Health Research (IDIS), Travesía da Choupana s/n, 15706 Santiago de Compostela, Spain; [email protected] (I.Z.-F.); [email protected] (M.G.-B.); [email protected] (E.B.-V.); [email protected] (V.M.S.) 3 Genomic Medicine Group, CIMUS, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain; [email protected] (N.G.-A.); [email protected] (O.M.) 4 Pharmacy Department, University Clinical Hospital of Santiago de Compostela (SERGAS), Citation: Toja-Camba, F.J.; 15706 Santiago de Compostela, Spain; [email protected] Gesto-Antelo, N.; Maroñas, O.; 5 Department of Pharmacy and Pharmaceutical Technology and Parasitology, University of Valencia, Echarri Arrieta, E.; Zarra-Ferro, I.; 46100 Valencia, Spain González-Barcia, M.; Bandín-Vilar, E.; 6 Interuniversity Research Institute for Molecular Recognition and Technological Development,
[Show full text]
The Synthesis of Tryptophan Derivatives, 2
Graduate Theses, Dissertations, and Problem Reports 2009 The synthesis of tryptophan derivatives, 2- and/or 3-substituted indoles, progress toward dilemmaones A-C, and synthetic studies towards fistulosin via palladium-catalyzed reductive N- heteroannulation Christopher Andrew Dacko West Virginia University Follow this and additional works at: https://researchrepository.wvu.edu/etd Recommended Citation Dacko, Christopher Andrew, "The synthesis of tryptophan derivatives, 2- and/or 3-substituted indoles, progress toward dilemmaones A-C, and synthetic studies towards fistulosin via palladium-catalyzed reductive N-heteroannulation" (2009). Graduate Theses, Dissertations, and Problem Reports. 4454. https://researchrepository.wvu.edu/etd/4454 This Dissertation is protected by copyright and/or related rights. It has been brought to you by the The Research Repository @ WVU with permission from the rights-holder(s). You are free to use this Dissertation in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in WVU Graduate Theses, Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU. For more information, please contact [email protected]. The Synthesis of Tryptophan Derivatives, 2- and/or 3- Substituted Indoles, Progress Toward Dilemmaones A-C, and Synthetic Studies Towards Fistulosin via Palladium-Catalyzed Reductive N-Heteroannulation Christopher Andrew Dacko Dissertation submitted to the Eberly College of Arts and Sciences at West Virginia University in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Chemistry Björn C.
[Show full text]
Name of Medicine
HALDOL® haloperidol decanoate NEW ZEALAND DATA SHEET 1. PRODUCT NAME HALDOL haloperidol decanoate 50 mg/mL Injection HALDOL CONCENTRATE haloperidol decanoate 100 mg/mL Injection 2. QUANTITATIVE AND QUALITATIVE COMPOSITION HALDOL 50 mg/ml Haloperidol decanoate 70.52 mg, equivalent to 50 mg haloperidol base, per millilitre. HALDOL CONCENTRATE 100 mg/ml Haloperidol decanoate 141.04 mg, equivalent to 100 mg haloperidol base, per millilitre. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Injection (depot) HALDOL Injection (long acting) is a slightly amber, slightly viscous solution, free from visible foreign matter, filled in 1 mL amber glass ampoules. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications HALDOL is indicated for the maintenance therapy of psychoses in adults, particularly for patients requiring prolonged parenteral neuroleptic therapy. 4.2 Dose and method of administration Administration HALDOL should be administered by deep intramuscular injection into the gluteal region. It is recommended to alternate between the two gluteal muscles for subsequent injections. A 2 inch-long, 21 gauge needle is recommended. The maximum volume per injection site should not exceed 3 mL. The recommended interval between doses is 4 weeks. DO NOT ADMINISTER INTRAVENOUSLY. Patients must be previously stabilised on oral haloperidol before converting to HALDOL. Treatment initiation and dose titration must be carried out under close clinical supervision. The starting dose of HALDOL should be based on the patient's clinical history, severity of symptoms, physical condition and response to the current oral haloperidol dose. Patients must always be maintained on the lowest effective dose. CCDS(180302) Page 1 of 16 HALDOL(180712)ADS Dosage - Adults Table 1.
[Show full text]